RAIZNER SLANIA TO ACCEPT XARELTO CLAIMS

The lawyers at Raizner Slania LLP are now accepting clients who have suffered an injury as a result of taking the blood thinner Xarelto. Our attorneys have extensive experience in similar pharmaceutical litigation, and previously represented over a 100 clients whose families suffered emotionally, physically and financially as a result of taking Paradaxa. Litigation surrounding Pradaxa settled last year for $650 million.

Xarelto is a new drug approved in 2011 for prevention of stroke in patients with atrial fibrillation. It is a part of new class of drugs called oral anti-coagulants. Xarelto claims to provide an improvement upon the standard therapy for atrial fibrillation, which for the last 50 years has been a drug called Warfarin, also known as Coumadin. Bayer and Janssen Pharmaceuticals, the makers of Xarelto, claim that the drug is as effective as Warfarin, but these claims, and the studies supporting them, appear to have been overstated. In reality, Bayer and Janssen rushed Xarelto to market before an antidote had been developed. The result – uncontrolled bleeding events without the possibility of reversal.

Part of the problem with Xarelto is that patients and their physicians have been sold the suggestion that they need not undergo the level of blood testing required with other therapies. For example, Warfarin patients are advised to undergo blood tests regularly in an effort to reduce the risk of a major bleeding event. Unlike Warfarin, the drug companies responsible for putting Xarelto on the market, have claimed in their advertisements and other promotional materials that Xarelto patients don’t need to have their blood tested.

Sadly, these claims appear to be false, and they have subjected thousands of patients worldwide to uncontrolled gastrointestinal bleeding, cerebral hemorrhage, stroke and other injuries. Research has shown that if Xarelto patients were to simply have their blood tested and then have their dose adjusted based on the results, their risk of a major bleed could be reduced by as much as 20 to 40 percent. Unfortunately, this information has not been shared with doctors or patients and the FDA has already received over a hundred reports of reactions and death related incidents.

If you or a loved one have experience a serious or fatal bleeding event while on Xarelto, contact the experienced Drug Litigation Attorneys at Raizner Slania immediately to discuss and preserve your legal rights.

Sharing is caring!